ADCV02 / Ever Supreme Bio Tech - LARVOL DELTA

Changsheng: Product and technology transfer revenue will boost operations in the first quarter, which will be better than the same period last year [Google translation] (stock.yahoo) - "Changsheng communicated with the media today. Liu Zhuqi said that its products include dendritic cell vaccine (ADCV01), second-generation dendritic cell vaccine (ADCV02), CIK (cytokine-induced killer cells), new cell therapy Gamma delta T and DC-CIK (dendritic cell combined with cytokine-induced killer cells), etc., after optimization, the gross profit margin is higher and the turnover rate is faster....Changsheng said that the gross profit of ADCV02 increased by 10% compared with the first generation."

Sales • Oncology • Solid Tumor